NEW YORK, July 30, 2026, 15:04 EDT — U.S. equities trading underway
- At 2:48 p.m. EDT, GlucoTrack shares were priced at $0.557, an increase of 95.4%. Trading volume totaled 246.8 million shares.
- Initial estimates show a $900,000 debt swap may result in the issuance of approximately 2.9 million shares, or close to 37% of the total common shares as of July 17.
- Lōkahi plans to begin clinical testing of its one-time LT-100 injection as soon as the fourth quarter, with first results potentially available in the first half of 2027.
Shares of GlucoTrack jumped as Lōkahi Therapeutics proposed an easier pathway for LT-100. The fully owned subsidiary is seeking approval for a single subcutaneous injection rather than as many as 15 intradermal injections.
The headline shift was striking. The implications for common shareholders could be more significant when it comes to financing calculations.
A new regulatory filing revealed an updated agreement to convert $900,000 in debt to equity. The stock price is determined by the lower value between the last Nasdaq closing price or the average over five sessions.
The filing did not disclose the resulting price. Recent closing prices suggest approximately $0.31—lower than the five-day average of around $0.38. This gives an initial projection of close to 2.9 million shares exchanged.
| Debt swap date | Amount of debt swapped | Shares included or projected | Implied share price | Shares per $1 million of debt |
|---|---|---|---|---|
| April 13 | $0.600 million | 0.895 million | $0.670 | 1.49 million |
| April 29 | $0.988 million | 1.300 million | $0.760 | 1.32 million |
| July 24 revised | $0.900 million | Roughly 2.9 million | Roughly $0.31 | Roughly 3.2 million |
July numbers are provisional. GlucoTrack has not released the definitive “Minimum Price.” April data are based on shares and principal reported in the quarterly filing. SEC
The July projection represents approximately 37% of the 7.719 million shares disclosed on July 17. This figure is over twice the number of shares allocated per debt dollar compared to April.
Trading volume reinforced the observation. By 2:48 p.m. EDT, approximately 246.8 million shares had been traded. This figure is close to 32 times higher than the typical amount recorded on July 17. Shares may be bought and sold more than once.
The action also diverged significantly from comparable peers.
| Security | Price | Intraday change |
|---|---|---|
| GlucoTrack, Inc. NASDAQ:GCTK | $0.557 | +95.4% |
| Senseonics Holdings, Inc. (NYSEAMERICAN:SENS) | $5.15 | +5.7% |
| DexCom, Inc. NASDAQ:DXCM | $73.81 | -1.8% |
| Abbott Laboratories NYSE:ABT | $105.81 | -2.0% |
| SPDR S&P Biotech ETF (NYSEARCA:XBI) | $150.06 | +1.5% |
The disparity indicates a catalyst unique to the company, not a broader move across the sector. It also highlights how rapidly a limited pool of common shares can change hands.
The LT-100 announcement outlined a nonclinical study in minipigs focusing on systemic exposure levels. No clinical efficacy data was provided. The research evaluated both subcutaneous and intradermal delivery methods.
CEO Erik Emerson said, “The difference between 15 injections and one injection speaks for itself.” Management indicated that clinical trials may start in the fourth quarter, though this schedule depends on progress in development and regulatory assessment. Business Wire
Funding continues to be a key issue. GlucoTrack reported having $3.929 million in cash as of March 31. The company recorded $4.048 million in cash used for operational activities in the quarter, while net loss totaled $4.334 million.
| Capital measure | Amount | Context |
|---|---|---|
| Cash as of March 31 | $3.929 million | Decreased from $7.383 million at end of previous year |
| First-quarter operating cash outflow | $4.048 million | Occurred before the Lōkahi merger |
| First-quarter net loss | $4.334 million | Compared with $6.833 million for the same period last year |
| Bridge financing on July 14 | Roughly $4.45 million gross | 22% original-issue discount, 8% interest rate, nine-month term |
The bridge represented almost a quarter of operating cash consumed before the merger. With its discount, interest rate, and brief maturity, it is an expensive source of capital. Once shareholders approve, the notes may also be converted into common shares.
The July 14 merger introduces another element. Lōkahi shareholders were issued common and preferred stock intended to secure 90% fully diluted ownership. Current GlucoTrack holders maintain a minimum 10% ownership following conversion.
The conversion is contingent on getting both shareholder and Nasdaq approval. A reverse stock split of up to 1-for-30 is also on the agenda for the annual meeting scheduled for August 18. The newly exchanged shares must be delivered by August 31, with ownership limited to a maximum of 9.99%.
Risks: The study assessed drug exposure instead of actual clinical benefit. Company-set development timelines are unchanged. Additional dilution may occur from debt exchanges, preferred share conversions, bridge securities or equity-line sales. Nasdaq began delisting proceedings due to shares trading below $1, an action GlucoTrack plans to contest.
Investors face a dual challenge. LT-100 needs to advance to clinical trials, and securing funding must maintain sufficient value for holders of common shares.
